I know @Davisite says we're more advanced than what some media states, but having a look at the full program, I believe clarity is still earlier than its peers.
255ac is in the main prostate cancer speaking program, whilst clarity is speaking in a program where they're still discussing the viability of cu64/67.
I believe this shows why moves were made for other radioconjugates, and we're still moving forward. I hope this stays the case until we at least release our P1/2 data. P1 255ac has been out for years, whereas clarity hasn't formally released and Journal articles about their cu67, as it's still in progress.
CU6 - Media and Industry News, page-26
-
- There are more pages in this discussion • 605 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.83 |
Change
-0.020(0.29%) |
Mkt cap ! $2.187B | |||
| Open | High | Low | Value | Volume |
| $6.83 | $7.05 | $6.58 | $11.93M | 1.755M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1461 | $6.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.90 | 3341 | 2 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |